ArticleClinical & experimental metastasis2009
Transient RNA silencing of tissue factor pathway inhibitor-2 modulates lung cancer cell invasion.
Article in Clinical & experimental metastasis, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 44 citations in OpenAlex.
- High IntratumoralInternational journal of molecular sciences · 2026Pooled it
- TFPI2 in tumor metastasis: a double-edged sword with clinical implications.Cancer biology & therapy · 2026Review
- The presence of cancer-associated fibroblast in breast cavity side margins is in correlation with the expression of oncoproteins by adjacent epithelial cells: a new era in cancerous potential.Journal of cancer research and clinical oncology · 2024Article
- New Derivatives ofInternational journal of molecular sciences · 2023Article
- Tissue Factor Pathway Inhibitors as Potential Targets for Understanding the Pathophysiology of Preeclampsia.Biomedicines · 2023Review
- Association of MMP-2 and MMP-9 Polymorphisms with Diabetes and Pathogenesis of Diabetic Complications.International journal of molecular sciences · 2022Review
- MicroRNA-23a acts as an oncogene in pancreatic carcinoma by targeting TFPI-2.Experimental and therapeutic medicine · 2020Article
- Overexpression of tissue factor pathway inhibitor 2 attenuates trophoblast proliferation and invasion in preeclampsia.Human cell · 2020Article
- Elevated MMP9 expression in breast cancer is a predictor of shorter patient survival.Breast cancer research and treatment · 2020Article
- Gambogic acid suppresses colon cancer cell activityExperimental and therapeutic medicine · 2019Article
- Golgin-160 and GMAP210 play an important role in U251 cells migration and invasion initiated by GDNF.PloS one · 2019Article
- Study on the expression of p53 and MMP-2 in patients with lung cancer after interventional therapy.Oncology letters · 2018Article
- The relationship between MMP-2 and MMP-9 expression levels with breast cancer incidence and prognosis.Oncology letters · 2017Article
- Precursor N-cadherin mediates glial cell line-derived neurotrophic factor-promoted human malignant glioma.Oncotarget · 2017Article
- Decreased expression of TFPI-2 correlated with increased expression of CD133 in cholangiocarcinoma.International journal of clinical and experimental pathology · 2015Article
- Methylation-induced downregulation of TFPI-2 causes TMPRSS4 overexpression and contributes to oncogenesis in a subset of non-small-cell lung carcinoma.Cancer science · 2015Article
- FRAS1 knockdown reduces A549 cells migration and invasion through downregulation of FAK signaling.International journal of clinical and experimental medicine · 2014Article
- Beneficial role of overexpression of TFPI-2 on tumour progression in human small cell lung cancer.FEBS open bio · 2013Article
- Reduced expression of tissue factor pathway inhibitor-2 contributes to apoptosis and angiogenesis in cervical cancer.Journal of experimental & clinical cancer research : CR · 2012Article
- CD24 promotes tumor cell invasion by suppressing tissue factor pathway inhibitor-2 (TFPI-2) in a c-Src-dependent fashion.Clinical & experimental metastasis · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tissue Factor Pathway Inhibitor-2 (TFPI-2) is a potent inhibitor of plasmin which activates metalloproteinases (MMPs) involved in extracellular matrix (ECM) degradation. Its secretion in ECM makes TFPI-2 a potential inhibitor to regulate tumour invasion and metastasis. Moreover, TFPI-2 is frequently downregulated, particularly in aggressive cancers. In this study, we silenced TFPI-2 in the NCI-H460 non-small cell lung cancer cell line and evaluated the role of TFPI-2 in cell invasion and its impact on MMPs expression. As the effects of siRNA are transient, the consequences of both gene silencing and restoration to normal expression could be studied kinetically in the same cells. We showed that TFPI-2 expression by NCI-H460 cells was effectively downregulated using specific small interfering RNA and this silencing was associated with an increase in the invasive potential of tumour cells while migration was not affected. We also showed that mRNA levels and protein expression of MMP-2, -3, -9, -14 were not influenced by TFPI-2 silencing. Moreover, the gelatinase activity of MMP-2 and MMP-9 was unmodified. In contrast, MMP-1 mRNA levels and protein were significantly and similarly increased in cells transfected with TFPI-2 siRNA. In conclusion, this study confirms that TFPI-2 downregulation can contribute to tumour invasion of lung cancer cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.